Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab) ...

Please provide your email address to receive an email when new articles are posted on . Postmenopausal women assigned denosumab have increases in mineral to matrix ratio at the cortical and cancellous ...

Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, interchangeable with Prolia and Xgeva, respectively. Clinical trials confirmed ...

Please provide your email address to receive an email when new articles are posted on . Hypocalcemia risk increased with worsening CKD stages, particularly for patients on dialysis. Emergently treated ...

The study of postmenopausal women in Iran found the efficacy of the biosimilar was noninferior to the reference product and the safety was comparable after 18 months. As the global population ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and ...

During the first 12 weeks of treatment, 41.1% of women on denosumab developed severe hypocalcemia compared with 2.0% of those taking oral bisphosphonates, reported a group of largely FDA researchers ...

Dr. Reddy’s and Alvotech have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia and Xgeva (denosumab). The collaboration ...